Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

DAYTRANA that was launched last year, represented 32% of our fourth quarter product sales.

The acquisition of New River Pharmaceuticals gave us full ownership and control of VYVANSE, and this new generation ADHD treatment is establishing itself in the US, where it has already gained a market share of 6%(i). The launch of VYVANSE continues to progress well and we are confident about the medication's future growth supported by new clinical studies and expected additional indications. Our total ADHD franchise has now grown to 32% of the total US ADHD market, compared to 28% at the end of 2006, extending our leadership position in this specialist area.

We've also acquired five pipeline compounds in new technologies and new markets, by licensing the marketing and co-development rights to a range of both biological and small molecule products from Renovo, Amicus Therapeutics and Alba Therapeutics.

Looking forward, we will continue to execute our strategy, which has provided good returns for shareholders, by building on the success of our growing specialist drugs portfolio focused on the treatment of symptomatic diseases. We currently expect 2008 revenue growth to be in the mid to high teens range and positive revenue growth through 2010."

(i) per IMS weekly prescription data at February 8, 2008

Product Highlights

- VYVANSE(TM) - Attention Deficit and Hyperactivity Disorder ("ADHD").

- Approved by the US Food and Drug Administration ("FDA") for use in the pediatric population in February 2007 and launched in the US in July 2007 (dosage strengths 30mg, 50mg and 70mg).

- On December 10, 2007 the FDA approved three additional dosage strengths (20mg, 40mg and 60mg) which will be available in retail pharmacies in the US in the second quarter of 2008. These additional strengths are designed to increase dosing flexibility.

- By February 15, 2008 VYVANSE had achieved a US ADHD market share of 6.3% based on daily presc
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015   ... in liquid photopurification, announced today that the Company ... for the continued trading of SurePure ("SURP") securities ... venture marketplace for entrepreneurial and development stage companies. ... Group introduced standards and eligibility requirements designed to ...
(Date:3/27/2015)... SHANGHAI , March 27, 2015 ... a leading open-access R&D capability and technology platform ... device industries, announced today that an Investigational New ... monoclonal antibody for rheumatoid arthritis has been accepted ... Administration (CFDA).  In September 2012, ...
(Date:3/26/2015)... Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... for the detection of foodborne pathogens, today reported ... full year ended December 31, 2014. ... ended December 31, 2014 was $1.4 million compared ... and $1.5 million for the third quarter of ...
(Date:3/26/2015)... CO (PRWEB) March 26, 2015 The ... has formed a strategic alliance with Designing Gig LLC ... their clients. , “Forging this alliance with ... Now we can extend a comprehensive, end-to-end, digital ... development, strategy, and execution,” said Chuck Miller, president of ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2
... Bulletin Board: DSCI), a provider of advanced wound care ... based on a,number of new products that are finding ... direct salespersons in the US a year ago, now,has ... increase is a significant one,for Derma Sciences, which has ...
... pre-adoption clinical evaluation of ... Recent case of vCJD now means that all the population is susceptible to ... the disease, - Increased concerns over "second wave" of vCJD in individuals with much ... longer incubation times - P-Capt(R) prion reduction filter still the only proven method ...
... 17, 2008 Scientific studies on climate change, energy ... more than 145 million processing hours on supercomputers at ... Innovative and Novel Computational Impact on Theory and Experiment ... industry, academia and government research facilities receive access to ...
Cached Biology Technology:Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008 2Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008 3ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 2ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 3ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 4ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 5Oak Ridge leads DOE INCITE effort in 2008 2Oak Ridge leads DOE INCITE effort in 2008 3Oak Ridge leads DOE INCITE effort in 2008 4
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
(Date:3/12/2015)... , March 12, 2015 ... a standardized identity and access management (IAM) solution ... implementation schedule. With Beta System,s new IAM package, ... best practices gleaned from multiple IAM implementations across ... the software as well as any necessary services ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... allow women diagnosed with cancer the opportunity to have children ... researchers at the University of Michigan Comprehensive Cancer Center have ... cancer treatments, a woman can preserve the hope of one ... thawing them safely so they can lead to pregnancy is ...
... cause of death among children in developing regions of ... or international health organizations and charities, according to investigators ... of pediatric cancer is occurring as the number of ... the efforts of the World Health Organization and international ...
... critical inhibitory step that is a key component ... neutrophil production and destruction. The research, published in ... process for disposal of dying neutrophils is actively ... the processes that control neutrophil turnover may contribute ...
Cached Biology News:Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment 2Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment 3Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 2Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 3White Blood Cell 'Waste Disposal' System Plays Critical Regulatory Role 2
Apoptosis Detection Systems and Reagents...
...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: